Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity

Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab

(2017) A. Armuzzi et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis

(2016) Dao Xuan Nguyen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases

(2014) Lesley J. Scott   DRUGS

Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera

(2014) Petra Votavova et al.   IMMUNOLOGY LETTERS

Selective Tumor Necrosis Factor Receptor I Blockade Is Antiinflammatory and Reveals Immunoregulatory Role of Tumor Necrosis Factor Receptor II in Collagen-Induced Arthritis

(2014) Fiona E. McCann et al.   Arthritis & Rheumatology

Tumor necrosis factor α blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells

(2010) Hak-Ling Ma et al.   ARTHRITIS AND RHEUMATISM

Expression of Costimulatory TNFR2 Induces Resistance of CD4+FoxP3- Conventional T Cells to Suppression by CD4+FoxP3+ Regulatory T Cells

(2010) X. Chen et al.   JOURNAL OF IMMUNOLOGY

What have we learnt from targeted anti-TNF therapy?

(2009) M Feldmann et al.   ANNALS OF THE RHEUMATIC DISEASES